These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 25581761)

  • 1. Emerging biomarkers in the detection and prognosis of prostate cancer.
    Filella X; Foj L
    Clin Chem Lab Med; 2015 Jun; 53(7):963-73. PubMed ID: 25581761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New biomarkers in serum and urine for detection of prostate cancer].
    Stephan C; Jung K; Miller K; Ralla B
    Aktuelle Urol; 2015 Mar; 46(2):129-43. PubMed ID: 25897535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current biomarkers for diagnosing of prostate cancer.
    Stephan C; Jung K; Ralla B
    Future Oncol; 2015; 11(20):2743-55. PubMed ID: 26358139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.
    Hendriks RJ; van Oort IM; Schalken JA
    Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):12-19. PubMed ID: 27922627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen and other serum and urine markers in prostate cancer.
    Stephan C; Ralla B; Jung K
    Biochim Biophys Acta; 2014 Aug; 1846(1):99-112. PubMed ID: 24727384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers.
    Filella X; Foj L
    Int J Mol Sci; 2016 Oct; 17(11):. PubMed ID: 27792187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy.
    Perdonà S; Bruzzese D; Ferro M; Autorino R; Marino A; Mazzarella C; Perruolo G; Longo M; Spinelli R; Di Lorenzo G; Oliva A; De Sio M; Damiano R; Altieri V; Terracciano D
    Prostate; 2013 Feb; 73(3):227-35. PubMed ID: 22821756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy.
    De Luca S; Passera R; Fiori C; Bollito E; Cappia S; Mario Scarpa R; Sottile A; Franco Randone D; Porpiglia F
    Urol Oncol; 2015 Oct; 33(10):424.e17-23. PubMed ID: 26162485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers.
    Ferro M; Bruzzese D; Perdonà S; Mazzarella C; Marino A; Sorrentino A; Di Carlo A; Autorino R; Di Lorenzo G; Buonerba C; Altieri V; Mariano A; Macchia V; Terracciano D
    Clin Chim Acta; 2012 Aug; 413(15-16):1274-8. PubMed ID: 22542564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
    Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
    Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic accuracy of Prostate Health Index and urinary Prostate Cancer Antigen 3 in predicting pathologic features after radical prostatectomy.
    Cantiello F; Russo GI; Ferro M; Cicione A; Cimino S; Favilla V; Perdonà S; Bottero D; Terracciano D; De Cobelli O; Morgia G; Damiano R
    Urol Oncol; 2015 Apr; 33(4):163.e15-23. PubMed ID: 25575715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging biomarkers in the diagnosis of prostate cancer.
    Filella X; Fernández-Galan E; Fernández Bonifacio R; Foj L
    Pharmgenomics Pers Med; 2018; 11():83-94. PubMed ID: 29844697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Biomarkers for Prostate Cancer Detection and Prognosis.
    Filella X; Foj L
    Adv Exp Med Biol; 2018; 1095():15-39. PubMed ID: 30229547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of prostate cancer gene 3 score, prostate health index and percentage free prostate-specific antigen for differentiating histological inflammation from prostate cancer and other non-neoplastic alterations of the prostate at initial biopsy.
    De Luca S; Passera R; Bollito E; Manfredi M; Scarpa RM; Sottile A; Randone DF; Porpiglia F
    Anticancer Res; 2014 Dec; 34(12):7159-65. PubMed ID: 25503144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Diagnostic Biomarkers of Prostate Cancer: An Update.
    Anceschi U; Tuderti G; Lugnani F; Biava PM; Malossini G; Luciani L; Cai T; Marsiliani D; Filianoti A; Mattevi D; Costantini M; Misuraca L; Simone G
    Curr Med Chem; 2019; 26(6):1045-1058. PubMed ID: 30215331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue.
    Stephan C; Jung M; Rabenhorst S; Kilic E; Jung K
    Clin Chem Lab Med; 2015 Jun; 53(7):1109-18. PubMed ID: 25720086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Emerging biomarkers for the diagnosis, staging and prognosis of prostate cancer].
    Mazzola CR; Ghoneim T; Shariat SF
    Prog Urol; 2011 Jan; 21(1):1-10. PubMed ID: 21193139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine.
    Rigau M; Morote J; Mir MC; Ballesteros C; Ortega I; Sanchez A; Colás E; Garcia M; Ruiz A; Abal M; Planas J; Reventós J; Doll A
    Prostate; 2010 Dec; 70(16):1760-7. PubMed ID: 20672322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
    Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
    BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing prostate cancer screening; prospective randomized controlled study of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening program.
    Rubio-Briones J; Casanova J; Dumont R; Rubio L; Fernandez-Serra A; Casanova-Salas I; Domínguez-Escrig J; Ramírez-Backhaus M; Collado A; Gómez-Ferrer A; Iborra I; Monrós JL; Ricós JV; Solsona E; Salas D; Martínez F; Lopez-Guerrero JA
    Actas Urol Esp; 2014 May; 38(4):217-23. PubMed ID: 24169211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.